Searchable abstracts of presentations at key conferences on calcified tissues

ba0006oc15 | (1) | ICCBH2017

Fractures in school age children in relation to sex, ethnic background and bone mineral density: the generation R Study

Grgic Olja , Medina-Gomez Carolina , Trajanoska Katerina , Shevroja Enisa , Koromani Fjorda , Uitterlinden Andre , Jaddoe Vincent , Wolvius Eppo , Rivadeneira Fernando

Objectives: Previous studies indicate that about half of boys and one fourth of girls suffer a fracture before the age of 16 years. Similarly, children of European descent are more prone to fracture. Here we aimed to investigate at the population level the influence of sex, ethnic background and bone mineral density (BMD) on the occurrence of bone fractures in children of school age.Methods: This study (n=3,633 children with complete information...

ba0006p185 | (1) | ICCBH2017

Effects of vitamin D with calcium supplementation or zinc supplementation on the incidence of infections in school children: a randomized controlled trial

Mandlik Rubina , Ekbote Veena , Patwardhan Vivek , Chiplonkar Shashi , Khadilkar Vaman , Padidela Raja , Mughal Zulf , Khadilkar Anuradha

Objectives: Randomised controlled trials (RCTs) of vitamin D to reduce the incidence of infections among children have yielded variable results (Holland, 2012; Camargo, 2012). We performed a RCT of supplementation with vitamin D3 (cholecalciferol) along with calcium or supplementation with zinc in order to assess their effect on the incidence of infections in rural Indian school children.Methods: A double-blind, placebo-controlled RCT was conducted on 46...

ba0004p61 | (1) | ICCBH2015

Association of vitamin D concentrations with 7-Dehydrocholesterol Reductase in school children in a sun-rich, semi-rural setting in Western Maharashtra, India

Mandlik Rubina , Kajale Neha , Chiplonkar Shashi , Patwardhan Vivek , Ekbote Veena , Khadilkar Vaman , Mughal Zulf , Khadilkar Anuradha

Objectives: Studies have reported prevalence of vitamin D deficiency in Indian children with adequate sunlight exposure (Harinarayan, 2008). The objectives of our study were to A) examine the prevalence of vitamin D deficiency in children with adequate sunlight exposure in a semi-rural setting in Western Maharashtra (18(°N), India and B) explore the association of serum 7-Dehydrocholesterol reductase (7-DHCR) with the serum vitamin D levels.Methods:...

ba0002oc28 | Chronic diseases | ICCBH2013

Bone mineral density at diagnosis determines fracture rate in children-treated according to the DCOG-ALL9 protocol

te Winkel Mariel Lizet , Pieters Rob , Hop Wim C J , Roos Jan C , van der Sluis Inge M , Bokkerink Jos P M , Leeuw Jan A , Bruin Marrie C A , Kollen Wouter J W , Veerman Anjo J P , de Groot-Kruseman Hester A , van den Heuvel-Eibrink Marry M

Objectives: To elucidate the incidence and risk factors of skeletal toxicity in children with ALL treated with the dexamethasone-based DCOG-ALL9 protocol.Methods: Prospectively, the cumulative incidence of fractures was assessed in 672 patients and compared between different subgroups using the log-rank test. Serial measurements of bone mineral density of the lumbar spine (BMDLS) were performed in 399 ALL patients using dual energy X-ray absor...

ba0003pp404 | Other diseases of bone and mineral metabolism | ECTS2014

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha , Claessen Kim , Hamdy Neveen , Pereira Alberto , Biermasz Nienke

Background: Adult GH Deficiency (GHD) is associated with decreased bone mass and increased fracture risk. Recombinant human GH (rhGH) replacement therapy leads to progressive increases in bone mineral density (BMD) for up to 7 years of treatment, but little is known on longer term effects of rhGH therapy on bone mass or fracture risk.Methods: 230 GHD patients (mean age 47.1 years, 52.6% female) on rhGH replacement therapy for ≥5 years were included...

ba0005p35 | Bone biomechanics and quality | ECTS2016

Bone material properties as measured by Reference Point Indentation are low in subjects with acromegaly

Malgo Frank , Hamdy Neveen A T , Pereira Alberto M , Biermasz Nienke R , Appelman-Dijkstra Natasha M

Introduction: Acromegaly is a rare disease caused by excess growth hormone (GH) production by an adenoma of the anterior pituitary gland. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of a relatively normal Bone Mineral Density (BMD). There are no data on bone material properties in patients ...

ba0007p222 | (1) | ICCBH2019

Long-term clinical outcome in chronic recurrent multifocal osteomyelitis (CRMO): the Leiden cohort

Ramautar Ashna IE , Hamdy Neveen AT , Hissink-Muller Petra CE , Cate Rebecca ten , Appelman-Dijkstra Natasha M

Objectives: To characterize clinical features and long-term outcome of CRMO, a rare inflammatory bone disease of childhood and adolescence, which forms part of the spectrum of chronic non-bacterial osteomyelitis (CNO).Methods: We studied 33 patients with an established diagnosis of CRMO followed at the Centre for Bone Quality of the Leiden University Medical Center from 1994 to 2018. Demographic and clinical data were collected at presentation and last f...

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...